Photo by artlasovsky from unsplash
Key Points • Most patients with refractory B-ALL could achieve remission with a single infusion of CAR T cells.• Survival probability is excellent for patients who relapsed >6 months posttransplant… Click to show full abstract
Key Points • Most patients with refractory B-ALL could achieve remission with a single infusion of CAR T cells.• Survival probability is excellent for patients who relapsed >6 months posttransplant and poor for patients who relapsed before 6 months.
Keywords:
effective therapy;
cd19 car;
car;
cells effective;
car cells;
therapy post
Journal Title: Blood advances
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood advances
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!